Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
Vall d'Hebron Institute of Oncology · Vall d'Hebron Hospital Universitari · +39 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
200
total citations
- FWCI
- 54.40
- Percentile
- 100%
- References
- 25
Citations per year
Authors
119- AOAna OakninCorresponding
Vall d'Hebron Institute of Oncology, Vall d'Hebron Hospital Universitari
- LGLaurence Gladieff
Institut Claudius Regaud
- JMJerónimo Martínez-García
Hospital Universitario Virgen de la Arrixaca
- GVGuillermo Villacampa
Vall d'Hebron Institute of Oncology, Institute of Cancer Research
- MTMunetaka Takekuma
Shizuoka Cancer Center
Topics & keywords
Topics
Keywords
- Bevacizumab
- Atezolizumab
- Medicine
- Oncology
- Open label
- Chemotherapy
- Cervical cancer
- Internal medicine
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.